InvestorsHub Logo
Followers 1055
Posts 189434
Boards Moderated 1
Alias Born 06/19/2009

Re: kei post# 94793

Wednesday, 08/10/2016 9:41:03 AM

Wednesday, August 10, 2016 9:41:03 AM

Post# of 97237
KTOV If Pfizer or Teva can't beat them they should join them or buy them. Patent till 2029 for improved Celebrex worth at least 200m imo vs 20m current cap.

PV calculation based on patent yrs. on conservative sales prediction gives you a present value of $1.5b.

kitov last step is to file NDA by end of this year. I am feeling kitov might file earlier than expected. all milestones completely and w/ a former FDA chemist and a former FDA officer i expect things to go smoothly.
Kitov will have exclusive rights for many years in the US market. That's big money for any company,especially for $24m cap Co.

My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.